Osiris Therapeutics (NASDAQ:OSIR) on Tuesday, Aug 13 announced fantastic top line results from its Grafix phase III clinical trial for the treatment of chronic diabetic foot ulcers (DFUs). The trial met all primary and secondary endpoints, and did so convincingly that the trial was stopped for overwhelming efficacy. A summary of the top line results are reproduced below:
(click to enlarge)
The effect that these results had on the share price was (at least in my opinion) magnified by the significant short interest and low daily volume the stock carried with it. Below is Yahoo's reporting of the stock's "trading information" coming into the day.
With 16.5% of the float short and an impressive 30 days to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|